Ling Zhang

发表

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

Yang Feng, Boro Dropulic, Marianna Sabatino, 2017, Nature Medicine.

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

P. Sorensen, D. Teachey, S. Grupp, 2015, Blood.

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

R. Orentas, T. Fry, C. Mackall, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice

S. Rosenberg, R. Morgan, N. Restifo, 2012, Clinical Cancer Research.

Local Delivery of lnterleukin-12 using T cells Targeting Vascular Endothelial Growth Factor Receptor-2 Eradicates Multiple Vascularized Tumors in Mice

S. Rosenberg, R. Morgan, N. Restifo, 2012 .

Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family.

D. Tagle, P. Yu, T. Cai, 2006, Gene.

Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

S. Rosenberg, R. Morgan, N. Restifo, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Evaluation of &ggr;-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application

S. Rosenberg, R. Morgan, M. Dudley, 2012, Journal of immunotherapy.

Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models

S. Rosenberg, R. Morgan, N. Restifo, 2020, Journal for ImmunoTherapy of Cancer.

Tumor-specific CD8+ T cells expressing IL-12 eradicate established cancers in lymphodepleted hosts

G. Trinchieri, S. Rosenberg, P. Muranski, 2010 .

Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins.

R. Morgan, D. Abate-Daga, Zhili Zheng, 2014, Nucleic acid therapeutics.

Non-synergy of PD-1 blockade with T-cell therapy in solid tumors

J. Gulley, Christian S. Hinrichs, Ling Zhang, 2022, Journal for ImmunoTherapy of Cancer.

Therapeutic Evaluation of Epstein-Barr Virus-encoded Latent Membrane Protein-1 Targeted DNAzyme for Treating of Nasopharyngeal Carcinomas

Lifang Yang, Lunquan Sun, F. Tang, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

The position of the AUG start codon in MFG‐based γ‐retroviral vectors has a dramatic effect on translation‐dependent protein expression

W. Burns, R. Morgan, T. Frankel, 2011, The journal of gene medicine.

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

S. Rosenberg, M. Stetler-Stevenson, D. Stroncek, 2016 .

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

D. Dimitrov, M. Sabatino, R. Orentas, 2017, Nature medicine.

T Cell Immunotherapy: From Synthetic Biology to Clinical Practice

R. Orentas, Ling Zhang, 2015 .

Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

S. Rosenberg, R. Morgan, N. Restifo, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

M. Stetler-Stevenson, D. Stroncek, T. Fry, 2016 .

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

G. Trinchieri, S. Rosenberg, P. Muranski, 2010, Cancer research.

Cancer esearch oenvironment and Immunology or-Specific CD 8 + T Cells Expressing Interleukin-12 R dicate Established Cancers in Lymphodepleted Hosts

G. Trinchieri, S. Rosenberg, P. Muranski, 2010 .

Genetic engineering with T cell receptors.

R. Morgan, Ling Zhang, 2012, Advanced drug delivery reviews.

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails

S. Rosenberg, R. Morgan, N. Restifo, 2013, Cancer Immunology, Immunotherapy.

Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

Sadik H. Kassim, S. Rosenberg, R. Morgan, 2015, Clinical Cancer Research.

Pre-Clinical Development Of a Novel Chimerical Antigen Receptor Targeting High-Risk Pediatric ALL Over-Expressing Tslpr

S. Grupp, R. Orentas, T. Fry, 2013 .

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

S. Rosenberg, M. Stetler-Stevenson, D. Stroncek, 2015 .

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

D. Dimitrov, M. Sabatino, R. Orentas, 2017, Nature Medicine.

Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia

Ling Zhang, Tongtong Zhang, Deipei Wu, 2023, Blood advances.

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

S. Rosenberg, P. Muranski, R. Morgan, 2012, Gene Therapy.

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

G. Trinchieri, S. Rosenberg, P. Muranski, 2010, Cancer research.

Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

M. Stetler-Stevenson, D. Stroncek, T. Fry, 2015 .

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

S. Rosenberg, M. Sabatino, M. Stetler-Stevenson, 2014 .